---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-019314"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:20:34.488248+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IDEAYA reports Q4 2024 net loss of $130.3M; cash ~$1.1B, funds operations into at least 2028

## Summary
- Cash, equivalents and marketable securities of ~$1.1B as of Dec 31, 2024, up from $632.6M in 2023.
- Net loss for Q4 2024 was $130.3M vs $34.0M in Q4 2023; full-year net loss $274.5M vs $113.0M.
- R&D expenses surged to $140.2M in Q4 2024 from $38.8M, driven by $75M upfront for IDE849 license from Hengrui.
- Over 230 patients enrolled in darovasertib + crizotinib Phase 2/3 in 1L HLA-A2-negative MUM; median PFS readout by year-end 2025.
- Announced three development candidates: IDE892 (PRMT5), IDE034 (B7H3/PTK7 ADC), IDE251 (KAT6/7); INDs targeted in 2025.

## SEC filing metadata
- accession: 0000950170-25-019314
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017025019314/0000950170-25-019314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017025019314/idya-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-019314
- JSON: https://secwatch.observer/filing/0000950170-25-019314.json
- Plain text: https://secwatch.observer/filing/0000950170-25-019314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.